PHARMACOKINETICS AND EXPOSURE-RESPONSE ANALYSES OF TELISOTUZUMAB VEDOTIN IN PATIENTS WITH ADVANCED SOLID TUMORS: PRELIMINARY PHASE I RESULTS.

被引：0
|
作者：
Parikh, A. [1 ]
Menon, R. [2 ]
Afar, D. [1 ]
Naumovski, L. [1 ]
Friedel, A. [3 ]
Kasichayanula, S. [1 ]
Mensing, S. [3 ]
机构：
[1] AbbVie Inc, Redwood City, CA USA
[2] AbbVie Inc, N Chicago, IL USA
[3] AbbVie Deutschland GmbH & Co KG, Ludwigshafen, Germany
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2019年 / 105卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PII-085
引用
收藏
页码：S67 / S67
页数：1
相关论文
共 50 条
  • [21] Population Pharmacokinetics and Exposure-Response Analyses for Risankizumab in Patients with Active Psoriatic Arthritis
    Thakre, Neha
    D'Cunha, Ronilda
    Goebel, Aline
    Liu, Wei
    Pang, Yinuo
    Suleiman, Ahmed A.
    RHEUMATOLOGY AND THERAPY, 2022, 9 (06) : 1587 - 1603
  • [22] Population pharmacokinetics and exposure-response modeling analyses of guselkumab in patients with psoriatic arthritis
    Chen, Yang
    Miao, Xin
    Hsu, Chyi-Hung
    Zhuang, Yanli
    Kollmeier, Alexa
    Xu, Zhenhua
    Zhou, Honghui
    Sharma, Amarnath
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2022, 15 (03): : 749 - 760
  • [23] Axitinib plus crizotinib in patients with advanced solid tumors and metastatic renal cell carcinoma (mRCC): Preliminary phase Ib results.
    Michaelson, M. Dror
    Gupta, Shilpa
    Agarwal, Neeraj
    Szmulewitz, Russell Zelig
    Powles, Thomas
    Pill, Roberto
    Bruce, Justine Yang
    Vaishampayan, Ulka N.
    Larkin, James M. G.
    Rosbrook, Brad
    Lechuga, Mariajose
    Valota, Olga
    Tarazi, Jamal Christo
    Shepard, Dale Randall
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [24] Pimavanserin Exposure-Response Analyses in Patients With Schizophrenia Results From the Phase 2 ADVANCE Study
    Darwish, Mona
    Bugarski-Kirola, Dragana
    Passarell, Julie
    Owen, Joel
    Jaworowicz, David
    DeKarske, Daryl
    Stankovic, Srdjan
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2022, 42 (06) : 544 - 551
  • [25] Tepotinib exposure-response analyses of safety and efficacy in patients with solid tumours
    Paik, P. K.
    Xiong, W.
    Hietala, S. F.
    Nyberg, J.
    Papasouliotis, O.
    Anziano, R.
    Berghoff, K.
    Johne, A.
    Girard, P.
    Strotmann, R.
    ANNALS OF ONCOLOGY, 2020, 31 : S494 - S495
  • [26] Efficacy and safety exposure–response analyses of entrectinib in patients with advanced or metastatic solid tumors
    Francois Mercier
    Nassim Djebli
    Mario González-Sales
    Felix Jaminion
    Georgina Meneses-Lorente
    Cancer Chemotherapy and Pharmacology, 2022, 89 : 363 - 372
  • [27] Population Pharmacokinetics and Exposure-Response Analysis of nab-Paclitaxel in Pediatric Patients With Recurrent or Refractory Solid Tumors
    Li, Yan
    Kassir, Nastya
    Chen, Nianhang
    Wang, Xiaomin
    Palmisano, Maria
    Zhou, Simon
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2021, 10 (02): : 115 - 130
  • [28] EXPOSURE-RESPONSE ANALYSIS OF ENTRECTINIB SUPPORTS THE RECOMMENDED DOSE IN PATIENTS WITH ADVANCED/METASTATIC SOLID TUMORS.
    Mercier, F.
    Djebli, N.
    Gonzalez-Sales, M.
    Meneses-Lorente, G.
    Jaminion, F.
    Phipps, A.
    Frey, N.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S50 - S50
  • [29] PHASE I STUDY OF THE PHARMACOKINETICS AND TOLERABILITY OF EVEROLIMUS IN CHINESE PATIENTS WITH ADVANCED SOLID TUMORS
    Xu, B.
    Shen, L.
    Ye, D.
    Jappe, A.
    Cherfi, A.
    Wang, H.
    Yuan, R.
    Wu, Y.
    ANNALS OF ONCOLOGY, 2010, 21 : 178 - 178
  • [30] A phase I pharmacokinetics study of 9-nitrocamptothecin in patients with advanced solid tumors
    Yan, Zhao
    Zhu, Zhongling
    Li, Kai
    Chen, Peng
    Wang, Liuchun
    Huang, Chun
    Xue, Jinhuai
    Liu, Meijun
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 67 (04) : 955 - 961
12345